Related Experiment Video
Updated: Feb 13, 2026

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
Published on: November 14, 2018
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting
Fabio Sonvico1,2, Adryana Clementino3,4, Francesca Buttini5,6
1Interdipartmental Center for Innovation in Health Products, BIOPHARMANET TEC, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy. fabio.sonvico@unipr.it.
Abstract:
In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer's disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose's upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Overview
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Bioavailability
Nose and Nasal Cavity
Modified-Release Drug Delivery Systems: Rate-Programmed II

